Social media

Join us at ACoP 2025 for two in-person workshops on October 17th, designed to help you build confidence and gain practical tools for delivering impactful NONMEM presentations. Workshop 1 : New and advanced features of N...

Pediatric clinical trials have different processes, risks and challenges than adult trials. Identifying those differences is critical but can be difficult, especially if resources are limited. Join ICON’s Heather Peterso...

Clinical development processes for pediatric trials differ from adult trials. Register for our webinar to learn about regulatory strategies and tools needed to ensure pediatric access to medical treatment and an interact...

Mental health conditions are now the second leading cause of long-term disability globally and the third leading cause of death for young people aged 15-29 years. ICON is committed to raising awareness and generating cha...

As awareness of mental health disorders grows, the demand for effective, tech-driven solutions is rising. Our whitepaper explores how SaMD is shaping the future of treatment - offering strategies for successful clinical ...

At #IRT2025, ICON joins industry leaders to discuss how sponsors and sites can align on investigational drug accountability. From internal IRT systems to third-party platforms, we’ll explore the challenges and opportunit...

Conducting a high-quality SLR requires more than just data - it demands strategic thinking, methodological rigor, and deep therapeutic expertise. ICON’s tailored approach delivers actionable insights that support regulat...

Are we measuring what matters in women’s health? Despite growing awareness, most clinical trials still rely on outcome assessments designed for men. This leads to misdiagnosed symptoms, delayed care, and poorer health o...

Did you know that more than 1 billion people worldwide live with mental health conditions such as anxiety and depression? ICON is a proud supporter of World Mental Health Day and over the past 5 years, has conducted 100+...

Join us at #IRT2025 as we explore the evolving landscape of IMP management. ICON’s Mia Carter will join a panel discussing the tension between sponsor mandates and site autonomy, and how collaboration can drive regulator...

Are biomarkers the key to reversing high failure rates in neurodegenerative trials? Biomarkers are no longer just exploratory tools, they’re central to improving trial precision and outcomes. Join Dr. Peter Schueler, MD...

Latest issue out now. If you, like our thousands of subscribers, would like a convenient way to keep on top of the latest regulatory authority updates, sign up to our free newsletter today: https://ow.ly/UlO350X4NqJ C...